Status:
COMPLETED
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.
Eligibility Criteria
Inclusion
- Key inclusion criteria
- Male with both parents of Japanese descent
- Body mass index (BMI) between 25.0 and 34.9 kg/m\^2 (both inclusive). Body weight equal to or greater than 65.0 kg
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
- Key exclusion criteria
- Any disorder that in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
Exclusion
Key Trial Info
Start Date :
September 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06049329
Start Date
September 14 2023
End Date
December 15 2023
Last Update
March 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hakata Clinic
Fukuoka, Japan, 812-0025